Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into ADMA Biologics Inc's Possible Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / December 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
Can Adma Biologics (ADMA) Climb 25.5% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ADMA Biologics, Inc. Is Being Looked Into For Securities Fraud And Investors With Losses Are Invited To Assist The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV
ADMA Biologics is a rapidly growing player in plasma-derived therapies, with a 78% YoY revenue increase and a 1,300% YoY net income boost. The company's key product, ASCENIV, is expected to drive significant revenue growth and improve margins, supported by a completed pediatric trial and upcoming sBLA submission. Past legal controversies about an auditor's resignation caused temporary investor concerns, but now appear resolved with KPMG's appointment as ADMA's new accounting firm.
ADMA Biologics, Inc. Is Being Investigated For Fraud And Impacted Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
The Schall Law Firm Encourages Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
ADMA Biologics, Inc. Is Being Investigated For Committing Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
The Schall Law Firm Invites Stockholder Contributions To An Inquiry Into ADMA Biologics Inc's Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Here is how Adma Biologics (ADMA) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
